NYSE: HAE · Industrial Applications and Services · 5 alerts · CIK 313143
Share price
$121.34Close, Nov 16
Market cap
$5.53B
Shares outstanding
45.54MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Haemonetics Corp filings on SEC EDGAR ↗
Haemonetics VP, CAO Farris Maryanne Maunsell Sells $101K of Stock
Farris Maryanne Maunsell, VP, CAO, sold 836 shares of Haemonetics Corp at $120.99 a share, worth $101K in total on Nov 11, 2026. Shares held after the trade: 5,828 (-12.5%).
Haemonetics delivered strong Q2 results with 10% organic revenue growth, raising full-year guidance driven by a major CSL relationship expansion and Persona Plus adoption despite near-term margin pressure from growth investments.
Haemonetics Corp reported net revenues of $357.8 million for the quarter ended September 26, 2026, a 9.3% increase compared to the prior year. Net income rose to $46.3 million, driven by higher gross profits and the absence of intangible asset impairments that occurred in the previous year's quarter.
Haemonetics reported second quarter fiscal 2027 revenue of $358 million, a 9% increase driven by strong performance in its Apheresis business. The company achieved GAAP diluted EPS of $1.00 and adjusted diluted EPS of $1.35, benefiting from gross margin expansion and the transformation of its product portfolio toward higher-margin offerings.
Term
Q2 2027
“Our second-quarter and first-half results reflect significant momentum across our businesses. Expansion of our CSL relationship and recent innovation milestones in both Apheresis and MedSurg strengthen our competitive position and create powerful new opportunities. With multiple catalysts for growth, we are focused on executing for our customers and translating our momentum into sustained success and shareholder value.”